{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:32:57Z","timestamp":1787884377675,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.aed.2025.12.001","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T07:59:53Z","timestamp":1765180793000},"page":"212-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-7148","authenticated-orcid":false,"given":"Scott","family":"Reule","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Pickthorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areef","family":"Ishani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.aed.2025.12.001_bib1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/M23-2788","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American college of physicians","volume":"177","author":"Qaseem","year":"2024","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.aed.2025.12.001_bib2","first-page":"S11","article-title":"Improving care and promoting health in populations: standards of care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.aed.2025.12.001_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/20503121241261204","article-title":"Cardioprotective effects of sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase 4 inhibitor in type 2 diabetes: a meta-analysis of comparative safety and efficacy","volume":"12","author":"Shrestha","year":"2024","journal-title":"SAGE Open Med"},{"issue":"8","key":"10.1016\/j.aed.2025.12.001_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.amjmed.2024.04.032","article-title":"Combined sodium-glucose-transporters inhibitors and glucagon-like-peptide receptor agonist compared with monotherapy improves long-term survival: a real-world registry","volume":"137","author":"Garc\u00eda-Vega","year":"2024","journal-title":"Am J Med"},{"key":"10.1016\/j.aed.2025.12.001_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.aed.2025.12.001_bib6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7326\/M23-1490","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the American college of physicians","volume":"177","author":"Drake","year":"2024","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.aed.2025.12.001_bib7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrendo.2016.86","article-title":"Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus","volume":"12","author":"Tahrani","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.aed.2025.12.001_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10157","key":"10.1016\/j.aed.2025.12.001_bib9","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.aed.2025.12.001_bib10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12020-016-1166-4","article-title":"Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure","volume":"57","author":"Arturi","year":"2017","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.aed.2025.12.001_bib11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ehf2.12334","article-title":"Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial","volume":"5","author":"Sharma","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"10","key":"10.1016\/j.aed.2025.12.001_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13007","article-title":"Liraglutide relieves cardiac dilated function than DPP-4 inhibitors","volume":"48","author":"Hiramatsu","year":"2018","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"10.1016\/j.aed.2025.12.001_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.aed.2025.12.001_bib14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.aed.2025.12.001_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.aed.2025.12.001_bib16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.aed.2025.12.001_bib17","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.aed.2025.12.001_bib18","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/bcp.13903","article-title":"Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study","volume":"85","author":"Phrommintikul","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.aed.2025.12.001_bib19","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/ehf2.12707","article-title":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)","volume":"7","author":"Tanaka","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"21","key":"10.1016\/j.aed.2025.12.001_bib20","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.aed.2025.12.001_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1053\/j.ajkd.2019.03.417","article-title":"Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a\/3b CKD","volume":"74","author":"Allegretti","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.aed.2025.12.001_bib22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.aed.2025.12.001_bib23","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE Study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.aed.2025.12.001_bib24","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.aed.2025.12.001_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.aed.2025.12.001_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1479164118782872","article-title":"Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: a randomized open-label prospective trial","volume":"15","author":"Takashima","year":"2018","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"10.1016\/j.aed.2025.12.001_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","article-title":"Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized Study","volume":"9","author":"Grunberger","year":"2018","journal-title":"Diabetes Ther"},{"issue":"5","key":"10.1016\/j.aed.2025.12.001_bib28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"10.1016\/j.aed.2025.12.001_bib29","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.aed.2025.12.001_bib30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.aed.2025.12.001_bib31","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.aed.2025.12.001_bib32","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and cystatin C-Based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.aed.2025.12.001_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1047-2797(01)00211-3","article-title":"Assessment of vital status in department of Veterans affairs national databases. comparison with state death certificates","volume":"11","author":"Dominitz","year":"2001","journal-title":"Ann Epidemiol"},{"issue":"7","key":"10.1016\/j.aed.2025.12.001_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.21037\/atm.2018.02.12","article-title":"Time-varying covariates and coefficients in cox regression models","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"issue":"5","key":"10.1016\/j.aed.2025.12.001_bib35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s13300-025-01722-x","article-title":"Combining GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes mellitus: a scoping review and expert insights for clinical practice utilizing the nominal group technique","volume":"16","author":"Yepes-Cort\u00e9s","year":"2025","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.aed.2025.12.001_bib36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.aed.2025.12.001_bib37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.aed.2025.12.001_bib38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","article-title":"Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes","volume":"84","author":"Edmonston","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.aed.2025.12.001_bib39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2022.01.042","article-title":"Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice","volume":"352","author":"Fu","year":"2022","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.aed.2025.12.001_bib40","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2337\/dc20-1890","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases","volume":"43","author":"Xie","year":"2020","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.aed.2025.12.001_bib41","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records","volume":"11","author":"Xie","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.aed.2025.12.001_bib42","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1038\/s41467-025-62891-8","article-title":"A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD","volume":"16","author":"Wu","year":"2025","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.aed.2025.12.001_bib43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.recesp.2024.07.004","article-title":"Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry","volume":"78","author":"Garc\u00eda-Vega","year":"2025","journal-title":"Rev Esp Cardiol (Engl Ed"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725001894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725001894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T03:27:17Z","timestamp":1777260437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915725001894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3050915725001894"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2025.12.001","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Association of Clinical Endocrinology.","name":"copyright","label":"Copyright"}]}}